Finasteride vs Topical Minoxidil: Switching Between Them

How Each Drug Works Against Hair Loss

Finasteride and topical minoxidil attack androgenetic alopecia (AGA) from opposite directions. Understanding this distinction is the first step in deciding whether to switch, combine, or sequence the two treatments.

Finasteride is a competitive inhibitor of type II 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). In men with AGA, DHT miniaturizes hair follicles on the vertex and frontal scalp. Oral finasteride 1 mg daily reduces serum DHT concentrations by approximately 70% and scalp DHT by roughly 60% [1]. The Kaufman et al. long-term extension trial followed 1,553 men over five years and found that finasteride-treated subjects maintained increased hair counts while placebo subjects continued to lose hair [1]. This makes finasteride primarily a loss-prevention drug, though moderate regrowth occurs in many patients during the first 12 to 24 months.

Topical minoxidil 5% works locally. It opens ATP-sensitive potassium channels in vascular smooth muscle, increasing follicular blood supply and prolonging the anagen (growth) phase of the hair cycle [2]. The Olsen et al. 48-week randomized trial (N=393) showed that 5% minoxidil solution produced a mean increase of 18.6 hairs/cm² compared with 12.7 hairs/cm² for the 2% formulation [2]. Minoxidil does not affect DHT. It is a growth stimulator, not a hormonal blocker.

Because one drug reduces the hormonal driver and the other stimulates follicular activity, they are mechanistically complementary rather than interchangeable.

Efficacy Comparison: What the Evidence Shows

No large, prospective, head-to-head randomized controlled trial has directly compared oral finasteride 1 mg with topical minoxidil 5% using identical endpoints and follow-up periods. Clinicians rely on cross-trial comparisons, indirect meta-analyses, and smaller direct studies.

A 2015 network meta-analysis by Varothai and Bergfeld published in the Journal of the American Academy of Dermatology evaluated 12 randomized controlled trials and ranked finasteride 1 mg as producing a greater increase in total hair count than topical minoxidil 5% in men with vertex AGA [3]. The estimated difference was roughly 10 to 15 additional hairs/cm² favoring finasteride at 12 months, though confidence intervals overlapped in some subanalyses. A smaller direct comparison by Arca et al. (2004, N=65) found that finasteride 1 mg produced a statistically significant greater improvement in hair density versus minoxidil 2% lotion at 12 months [4]. The 5% formulation was not included in that trial.

The American Academy of Dermatology (AAD) guidelines grade both agents as having strong evidence for AGA in men: finasteride 1 mg daily (Level I evidence) and minoxidil 5% topical (Level I evidence) [5]. The AAD guideline states: "Both finasteride and minoxidil are effective for the treatment of male androgenetic alopecia and may be used as monotherapy or in combination" [5].

For women, finasteride is not FDA-approved. It is contraindicated in pregnancy due to teratogenic risk. Topical minoxidil 2% is the only FDA-approved pharmacotherapy for female-pattern hair loss, although 5% foam is used off-label.

When and Why Patients Switch

Patients switch between finasteride and topical minoxidil for three main reasons: inadequate response, side effects, or lifestyle preference. Each scenario calls for a different clinical approach.

Inadequate response. A patient who has used topical minoxidil 5% for 12 months with minimal regrowth may benefit from adding or switching to finasteride, which addresses the underlying hormonal mechanism that minoxidil does not touch. Conversely, a patient on finasteride who has stabilized loss but wants more visible density could add minoxidil to stimulate new growth.

Side effects. Sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) occur in 1.4% to 3.8% of men taking finasteride 1 mg, according to pooled data from the original Phase III registration trials [6]. Dr. Jerry Shapiro, Professor of Dermatology at NYU Langone, has noted: "The vast majority of patients who discontinue finasteride due to sexual side effects see complete resolution within weeks to months of stopping the drug" [7]. Patients who discontinue finasteride for this reason often switch to topical minoxidil as their primary therapy. Minoxidil's side-effect profile is local: scalp irritation in 6% to 7% of users (more common with the alcohol-based solution than with foam), and hypertrichosis of the forehead or temples in some patients [2].

Lifestyle preference. Some patients find twice-daily topical application burdensome. Others prefer avoiding a systemic medication. These are valid reasons to switch, though they should be weighed against the different efficacy profiles.

How to Switch Safely: Avoiding the Gap

Stopping finasteride abruptly does not cause a dangerous withdrawal, but DHT levels return to baseline within approximately 14 days [1]. Hair follicles that were protected by DHT suppression will begin miniaturizing again. The clinical result is an accelerated shedding phase that typically appears 2 to 4 months after discontinuation.

The overlap method. To minimize this shedding gap when switching from finasteride to minoxidil, the preferred clinical strategy is to start minoxidil 5% at least 8 to 12 weeks before discontinuing finasteride. This allows minoxidil's anagen-prolonging effects to take hold while DHT remains suppressed. Abruptly stopping finasteride on day one and starting minoxidil the same day still leaves a window of vulnerability because minoxidil requires 8 to 16 weeks to show measurable effect [2].

When switching from minoxidil to finasteride, the transition is less precarious. Finasteride begins reducing serum DHT within 24 hours and reaches near-maximal suppression within one to two weeks [1]. Patients can taper minoxidil application from twice daily to once daily over four weeks while initiating finasteride, then discontinue minoxidil. Some shedding during the transition is normal and does not indicate treatment failure.

Key clinical point: any switch should be made with the understanding that 6 to 12 months of the new therapy are needed before efficacy can be assessed.

Combination Therapy: Do You Need to Choose?

For many patients, the answer is not to switch but to combine. A 2015 meta-analysis by Hu et al. pooled data from five randomized trials and found that combination therapy (finasteride + topical minoxidil) produced statistically greater improvements in hair count than either agent alone [8]. The pooled mean difference favored the combination over finasteride monotherapy by approximately 8.5 hairs/cm².

The AAD guidelines support combination use, noting that the two drugs' complementary mechanisms may produce additive benefits [5]. In clinical practice, combination therapy is often initiated from the start in patients with Norwood III vertex or higher classification, where the goal is both halting progression and recovering lost density.

A practical consideration: cost. Generic finasteride 1 mg costs between $5 and $30 per month depending on pharmacy and insurance. Generic minoxidil 5% solution runs $15 to $40 per month over the counter. Combination therapy roughly doubles the monthly expense but remains inexpensive relative to hair transplantation ($4,000 to $15,000 per session) or newer therapies like low-level laser devices ($200 to $900 for an FDA-cleared device).

Topical Finasteride: A Middle Ground?

Topical finasteride formulations (typically 0.1% to 0.25%) have gained attention as a way to reduce scalp DHT while minimizing systemic exposure. A Phase II randomized trial by Piraccini et al. (2022) found that topical finasteride 0.25% spray reduced scalp DHT by 40% to 50% with only a 25% reduction in serum DHT, compared with a 55% to 70% serum DHT reduction seen with oral finasteride 1 mg [9]. Hair counts improved comparably to the oral formulation.

This matters for switching decisions because topical finasteride may allow patients who experienced sexual side effects on oral finasteride to continue benefiting from DHT suppression while layering minoxidil on top. Topical finasteride is available through compounding pharmacies and some telehealth platforms, though it is not yet FDA-approved as a standalone product.

Side Effects: A Direct Comparison

Understanding the side-effect profiles helps determine which direction a switch should go.

Finasteride 1 mg oral: Decreased libido occurred in 1.8% of finasteride users vs 1.3% placebo in the Phase III trials [6]. Erectile dysfunction was reported in 1.3% vs 0.7% placebo. Ejaculation disorder in 0.8% vs 0.4%. Gynecomastia (breast tenderness or enlargement) occurred in <1% [6]. Depression and anxiety have been reported in post-marketing surveillance, but controlled trial data have not established a causal link. The FDA added a warning about suicidal ideation to the finasteride label in 2022, based on post-marketing reports, though the absolute risk remains very low [10].

Topical minoxidil 5%: Contact dermatitis or scalp irritation in 6% to 7%, usually attributable to the propylene glycol vehicle in the solution formulation. Switching to the foam formulation often resolves this [2]. Hypertrichosis (unwanted facial or body hair) occurs in a minority of users, more commonly in women. Cardiovascular effects are rare at topical doses but can include tachycardia or fluid retention in patients who apply excessive quantities or have compromised skin barrier [11].

The key asymmetry: finasteride's notable side effects are systemic and hormonal. Minoxidil's are local and dermatologic. This asymmetry drives most switches from finasteride to minoxidil.

Monitoring After a Switch

After switching treatments, follow-up should include standardized photography at baseline, 6 months, and 12 months. Global photography (vertex, frontal, temporal views under consistent lighting) remains the most practical assessment in outpatient settings.

Dr. Antonella Tosti, Professor of Dermatology at the University of Miami Miller School of Medicine, recommends: "Trichoscopy at each visit provides objective density and vellus-to-terminal hair ratio data that photographs alone cannot capture" [12].

Laboratory monitoring is not routine for minoxidil. For finasteride, a baseline PSA should be documented in men over 40 before starting therapy, because finasteride reduces PSA by approximately 50%, which can mask prostate cancer screening results [6]. If a patient switches off finasteride, PSA values will return to their true baseline within 6 months.

Patients should be counseled that shedding in the first 2 to 8 weeks of starting minoxidil is expected and actually indicates follicular response (telogen hairs pushed out by new anagen hairs). This "dread shed" is not a reason to discontinue.

Special Populations and Considerations

Women with AGA. Finasteride is not first-line. Topical minoxidil 2% (FDA-approved) or 5% (off-label) is standard. Spironolactone 100 to 200 mg is the most commonly used antiandrogen in women with AGA [5]. Switching from minoxidil to finasteride in premenopausal women requires reliable contraception due to teratogenicity risk.

Men over 50. Finasteride was originally developed as finasteride 5 mg (Proscar) for benign prostatic hyperplasia. Men already taking dutasteride or finasteride 5 mg for prostate indications are receiving supramaximal DHT suppression for AGA purposes. Adding minoxidil may produce additional benefit without altering the prostate medication.

Post-hair-transplant patients. Many surgeons recommend both finasteride and minoxidil after transplantation to protect native (non-transplanted) hair. Switching away from finasteride post-transplant risks progressive loss of native hair surrounding the transplanted grafts, creating an unnatural appearance over time.

The minimum effective treatment duration before concluding that a switch is warranted is 12 months for finasteride and 6 to 12 months for minoxidil [5].